Aurobindo Pharma Limited (BOM:524804)
India · Delayed Price · Currency is INR 1,549.65
-15.00 (-0.96%)
At close: Jul 13, 2026
Aurobindo Pharma Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Aurobindo Pharma stock has a consensus rating of "Buy" and an average price target of ₹1,565. The average 1-year stock price forecast is 0.98% higher than the current stock price, while the lowest is ₹1,185 (-23.53%) and the highest is ₹1,810 (+16.80%).
Price Target: ₹1,565 (+0.98%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Aurobindo Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 17 | 15 | 14 | 15 | 13 | 13 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 0 | 0 | 1 | 1 | 5 | 5 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 3 | 3 | 2 | 2 | 2 | 2 |
| Total | 28 | 26 | 25 | 26 | 28 | 28 |
Financial Forecast
Revenue This Year
391.76B
from 336.53B
Increased by 16.41%
Revenue Next Year
432.79B
from 391.76B
Increased by 10.47%
EPS This Year
77.05
from 61.11
Increased by 26.08%
EPS Next Year
89.30
from 77.05
Increased by 15.90%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 419.6B | ||
| Avg | 391.8B | ||
| Low | 366.7B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 24.7% | ||
| Avg | 16.4% | ||
| Low | 9.0% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 84.70 | ||
| Avg | 77.05 | ||
| Low | 68.40 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 38.6% | ||
| Avg | 26.1% | ||
| Low | 11.9% |